Precigen, Inc. - Common Stock (PGEN)
2.9400
+1.0900 (58.92%)
NASDAQ · Last Trade: Aug 17th, 2:04 PM EDT
Detailed Quote
Previous Close | 1.850 |
---|---|
Open | 2.600 |
Bid | 2.860 |
Ask | 2.870 |
Day's Range | 2.510 - 3.490 |
52 Week Range | 0.6513 - 3.490 |
Volume | 173,724,327 |
Market Cap | 742.11M |
PE Ratio (TTM) | -7.000 |
EPS (TTM) | -0.4 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 10,950,140 |
Chart
About Precigen, Inc. - Common Stock (PGEN)
Precigen Inc is a biotechnology company focused on developing innovative gene and cell therapies aimed at addressing a range of diseases, including cancer and genetic disorders. The company leverages its proprietary technologies to create advanced therapeutic solutions that aim to enhance the body's immune response and provide targeted treatment options. By utilizing its expertise in genetic engineering and immunology, Precigen works to bring transformative health solutions to patients while advancing the field of precision medicine. Read More
News & Press Releases
Loop Industries, Inc. (Nasdaq: LOOP) just inked a game-changing alliance with Shinkong Synthetic Fibers, part of Taiwan’s $ multi-billion Shin Kong Group , to accelerate worldwide adoption of Twist™ , Loop’s branded 100% recycled textile-to-textile polyester resin.
Via AB Newswire · August 15, 2025
Via Benzinga · August 15, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · August 15, 2025
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Via Chartmill · August 15, 2025
Via Benzinga · August 15, 2025
Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · August 15, 2025
Via Benzinga · August 15, 2025
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via Chartmill · August 15, 2025
Via Benzinga · August 15, 2025
Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.
Via Benzinga · August 15, 2025
Via Benzinga · August 15, 2025
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · August 15, 2025
Via Benzinga · August 15, 2025
The company stated that Papzimeos is now the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis.
Via Stocktwits · August 15, 2025
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · July 22, 2025
Via Benzinga · July 22, 2025
Via Benzinga · July 9, 2025
Via Benzinga · July 2, 2025
Via Benzinga · March 21, 2025

Via Benzinga · January 23, 2025

Stocks are struggling for direction in the first trading session of the year.
Via Talk Markets · January 2, 2025